Modulation of plus-maze behaviour in mice by the preferential D3-receptor agonist 7-OH-DPAT

Pharmacology Biochemistry and Behavior

Volumn 54, Issue 1, 1996, Pages 79-84

  Rodgers, R J ^a   Johnson, N J T ^a   Champion, A J ^a   Mills, S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

7 OH DPAT; anxiety; dopamine D3 receptors; elevated plus maze; ethology; risk assessment

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; HALOPERIDOL; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BEHAVIOR; BODY POSTURE; CONFERENCE PAPER; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; ETHOLOGY; EXPLORATORY BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0030008228     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02110-8     Document Type: Conference Paper

References (46)

1. 3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur. J. Pharmacol. 260: 177-181; 1994.
2. Belzung, C.; Cabib, S.; Fabiani, L.; Tolentino, P.; Puglisi-Allegra, S. LY 171555-induced hyperdefensiveness in the mouse does not implicate benzodiazepine receptors. Psychopharmacology 103:449-454; 1991.
3. Belzung, C.; Carletti, P.; Angelucci, F.; Puglisi-Allegra, S.; Cabib, S. Behavioral effects of Ro 41-9067: A novel dopamine receptor agonist. Drug Dev. Res. 27:425-433; 1992.
4. 2 receptor mRNA. Brain Res. 564:203-219; 1991.
5. Cabib, S.; Puglisi-Allegra, S. Opposite responses of mesolimbic dopamine system to controllable and uncontrollable aversive experiences. J. Neurosci. 14:3333-3340; 1994.
6. 3 dopamine receptors. Science 260: 1814-1816; 1993.
7. Cole, J. C.; Rodgers, R. J. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 4:573-580; 1993.
8. Cole, J. C.; Rodgers, R. J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze: Comparison with haloperidol. Psychopharmacology 114; 288-296; 1994.
9. Cook, L.; Davidson, A. B. Effects of behaviourally active drugs in a conflict-punishment procedure in rats. Garattini, S.; Mussini, E.; Randall, L. O., eds. The benzodiazepines. New York: Raven Press; 1973:327-345.
10. Costall, B.; Hendrie, C. A.; Kelly, M. E.; Naylor, R. J. Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology 26:195-200; 1987.
11. 2like" agonists. Neuropharmacology 32:509-510; 1993.
12. 3 receptor ligand. Eur. J. Pharmacol. 249: R9-R10; 1993.
13. Dixon, A. K.; Fisch, H. U.; McAllister, K. H. Ethopharmacology: A biological approach to the study of drug-induced changes in behavior. Adv. Study Behav. 19:171-204; 1990.
14. Dunn, A. J. Stress-related activation of cerebral dopaminergic systems. Ann. NY Acad. Sci. 537:188-205; 1988.
15. Finlay, J. M.; Zigmond, M. J.; Abercrombie, E. D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: Effects of diazepam. Neuroscience 64:619-628; 1995.
16. Gao, B.; Cutler, M. G. Effects of quinpirole on the behaviour shown by mice in the light-dark box and during social interactions. Neuropharmacology 32:93-100; 1993.
17. Gingrich, J. A.; Caron, M. G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16:299-321; 1993.
18. 3 receptors. Eur. J. Pharmacol. 272:R1-R3; 1995.
19. Hjorth, S.; Carlsson, A.; Engel, J. A. Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm. Psychopharmacology 92:371-375; 1987.
20. Imperato, A.; Puglisi-Allegra, S.; Zocchi, A.; Scrocco, M. G.; Casolini, P.; Angelucci, L. Stress activation of limbic and cortical dopamine release is prevented by ICS 205-930 but not diazepam. Eur. J. Pharmacol. 182:211-214; 1990.
21. Jackson D. M.; Westlind-Danielson, A. Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacol. Ther. 64:291-369; 1994.
22. Johnston, A. L.; File, S. E. Yohimbine's anxiogenic action: Evidence for noradrenergic and dopaminergic sites. Pharmacol. Biochem. Behav. 32:151-156; 1989.
23. Kebabian, J. W.; Calne, D. B. Multiple receptors for dopamine. Nature 277:93-96; 1979.
24. 3 receptor: Chinese hamsters or Chinese whispers? Trends Pharmacol. Sci. 15:47-48; 1994.
25. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 89:8155-8159; 1992.
26. Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 99:48-53; 1987.
27. 3 receptor agonist 7-OH-DPAT: Lack of mesolimbic selectivity. Eur. J. Pharmacol. 264:269-278; 1994.
28. 3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur. J. Pharmacol. 260:R3-R5; 1994.
29. Murai, T.; Koshikawa, N.; Kanayama, T.; Takada, K.; Tomiyama, K.; Kobayashi, M. Opposite effects of midazolam and β-carboline-3-carboxylate ethyl ester on the relase of dopamine from rat nucleus accumbens measured by in vivo microdialysis. Eur. J. Pharmacol. 261:65-71; 1994.
30. Pich, E. M.; Samanin, R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: Possible role of dopamine. Psychopharmacology 89:125-130; 1986.
31. 2 dopamine receptors in the defensive behavior of the mouse. Behav. Neural Biol. 50:98-111; 1988.
32. 2 dopamine receptor agonist LY 171555 induces catalepsy in the mouse. Pharmacol. Biochem. Behav. 30:765-768; 1988.
33. 2 dopamine receptor systems. Pharmacol. Biochem. Behav. 36:327-331; 1990.
34. Reinhard, J. F.; Bannon, M. J.; Roth, R. H. Acceleration by stress of dopamine synthesis and metabolism in prefrontal cortex: Antagonism by diazepam. Naunyn-Schmied. Arch. Pharmacol. 318:374-377; 1982.
35. Rickels, K.; Schweizer, E. E. Current pharmacotherapy of anxiety and panic. In: Meltzer, H. Y., ed. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:1193-1203.
36. Rodgers, R. J.; Cole, J. C.; Aboualfa, K.; Stephenson, L. H. Ethopharmacological analysis of the effects of putative "anxiogenic" agents in the mouse elevated plus-maze. Pharmacol. Biochem. Behav. 52:805-813; 1995.
37. Rodgers, R. J.; Johnson, N. J. T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:297-303; 1995.
38. 2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 49:985-995; 1994.
39. Salamone, J. D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61: 117-133; 1994.
40. Sanchez, C.; Arnt, J.; Costall, B.; Domeney, A. M.; Kelly, E.; Naylor, R. J. Sertindole: A limbic selective neuroleptic with potent anxiolytic effects. Drug Dev. Res. 34:19-29; 1995.
41. Seeman, P.; Van Tol, H. H. M. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:264-270; 1994.
42. Sibley, D. R.; Monsma, F. J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:61-69; 1992.
43. Simon, P.; Panissaud, C.; Costentin, J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol. Biochem. Behav. 45:685-690; 1993.
44. 3) as a target for neuroleptics. Nature 347: 146-151; 1990.
45. 3-receptor agonist (+)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. Neurosci. Lett. 187:45-48; 1995.
46. 3 receptors. Eur. J. Pharmacol. 263:235-243; 1994.